|
May 8
|
AstraZeneca and Daiichi’s Enhertu shows pCR rate improvement in breast cancer trial
|
|
May 7
|
AstraZeneca (LSE:AZN) Reports Positive Phase 3 Trial Results For Breast Cancer Treatment
|
|
May 7
|
Q1 2025 Arcus Biosciences Inc Earnings Call
|
|
May 7
|
Expediting parallel drug approval pathways is challenging, but rewarding
|
|
May 7
|
ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by THP before surgery showed statistically significant and clinically meaningful improvement in pathologic complete response in high-risk HER2-positive early-stage breast cancer in DESTINY-Breast11
|
|
May 7
|
EC approves AstraZeneca’s Calquence combo to treat MCL
|
|
May 7
|
Tempus AI Inc (TEM) Q1 2025 Earnings Call Highlights: Record Revenue Growth and Strategic ...
|
|
Apr 25
|
The Zacks Analyst Blog Highlights Tempus AI, AstraZeneca, iRhythm Technologies and SOPHiA GENETICS
|
|
Apr 25
|
Stocks to watch next week: Apple, Microsoft, Shell, HSBC, Lloyds and AstraZeneca
|
|
Apr 24
|
Tempus AI Stock Sees 21% Gain in 3 Days: Is it a Buy After AZN Deal?
|
|
Apr 24
|
Unveiling Astrazeneca (AZN) Q1 Outlook: Wall Street Estimates for Key Metrics
|
|
Apr 24
|
AstraZeneca enters $200m AI cancer pact with Tempus and Pathos
|
|
Apr 24
|
Can Biogen Keep the Beat Streak Alive This Earnings Season?
|
|
Apr 23
|
AstraZeneca pushes EU to spend more on drugs amid Trump tariffs threat
|
|
Apr 23
|
Drug firm bosses call for price increases in Europe amid tariff uncertainty
|
|
Apr 23
|
Why Tempus AI Stock Is Skyrocketing Today
|
|
Apr 22
|
Astrazeneca (AZN) Rises But Trails Market: What Investors Should Know
|
|
Apr 22
|
AstraZeneca rejoins leading U.S. drug lobby group after two-year absence
|
|
Apr 22
|
Daiichi and AstraZeneca’s Enhertu shows PFS benefits in breast cancer trial
|
|
Apr 21
|
Cellectis SA (CLLS) Q4 2024 Earnings Call Highlights: Strategic Collaborations and Financial ...
|